Research: 14.6% Paxlovid contraindication rate for hospitalized patients with Covid-19

Coronavirus, Health, Healthcare, Hospitalization, Infection, Paxlovid, Paxlovid Rebound, Side Effects

“We examined the prevalence of contraindications to nirmatrelvir-ritonavir in patients hospitalized with COVID-19. We hypothesized that the rate would be high in these patients.”

Of the 62 525 remaining patients .. (14.6%) had a medical contraindication to nirmatrelvir-ritonavir.

Prevalence of Contraindications to Nirmatrelvir-Ritonavir Among Hospitalized Patients With COVID-19 at Risk for Progression to Severe Disease



Research: Paxlovid of no benefit to the under-65’s




Image by Kches16414, CC BY-SA 4.0, via Wikimedia Commons


** This post was originally published on November 15, 2022 **